Ind-Swift Laboratories Ltd.
Fundamentals
- Market cap
- ₹1,747 cr
- P/E
- 42.18×
- ROE
- 21.35%
- Debt / equity
- 0.03
- 52-week range
- 87.15 — 201.50
Company snapshot
Ind-Swift Laboratories Ltd.
Pharmaceuticals
₹1,873 cr
P/E 45.22×
Latest quarter · Mar 2026
Sales₹170 cr
Net profit₹15 cr
Op. margin+12.1%
EPS₹1.74
Strength & growth
Debt / equity0.03×
Current ratio3.92×
Sales CAGR−0.4%
EPS CAGR+0.7%
The timeline — 2 notes on Ind-Swift Laboratories Ltd.
July 2026
- 10 Jul 26 · 7:15 PM IST Lead Lead · Credit · Small cap
Ind-Swift promoter group bets ₹137 cr on warrants at ₹196
Essix Biosciences will buy 7 million warrants convertible in 18 months, a 7% dilution, signalling promoter confidence after a sharp earnings decline.
- 07 Jul 26 · 7:23 PM IST Brief Brief · Credit · Small cap
Ind-Swift Labs board to consider fund raise after warrant lapse, stake sale
Board to evaluate preferential issue, rights issue, or QIP on July 10. Trading window stays shut. Move follows a lapsed warrant issue and a 7.5% stake sale by HCP Investments in April.